Gilead Sciences completes $21bn acquisition of Immunomedics: A new era in cancer treatment
Gilead Sciences, a leading US-based pharmaceutical giant, has successfully concluded its $21 billion acquisition of Immunomedics, a New Jersey-based biopharmaceutical company renowned for its advancements ... Read More
Gilead acquisition of Immunomedics : Pharma giant to gain access to breast cancer drug Trodelvy
Gilead acquisition of Immunomedics : US pharma giant Gilead Sciences has signed a $21 billion worth deal to acquire New Jersey-based biopharma company Immunomedics to ... Read More